{"id":10254,"date":"2023-11-06T15:45:50","date_gmt":"2023-11-06T15:45:50","guid":{"rendered":"https:\/\/infundpros.com\/business\/biontech-cuts-revenue-forecast-on-lower-demand-for-covid-jabs\/"},"modified":"2023-11-06T15:45:50","modified_gmt":"2023-11-06T15:45:50","slug":"biontech-cuts-revenue-forecast-on-lower-demand-for-covid-jabs","status":"publish","type":"post","link":"https:\/\/infundpros.com\/?p=10254","title":{"rendered":"BioNTech cuts revenue forecast on lower demand for Covid jabs"},"content":{"rendered":"<div>\n<p>Unlock the Editor\u2019s Digest for free<\/p>\n<p class=\"article__content-sign-up-topic-description\"><span>Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.<\/span><\/p>\n<p><iframe class=\"article__content-sign-up-iframe close\" scrolling=\"no\" id=\"signUpIframe\" data-prev-url=\"\/register\/in-article-sign-up?ft-content-uuid=d5b1f377-a34d-4a7a-86b7-2c833d860110\"><\/iframe><\/div>\n<div id=\"article-body\">\n<p>BioNTech has slashed about \u20ac1bn from its full-year revenue forecasts on the back of falling demand for its Covid-19 vaccine developed with Pfizer. <\/p>\n<p>The German biotech now expects revenue from Covid shots of about \u20ac4bn in 2023, down from its guidance of \u20ac5bn, issued in March.<\/p>\n<p>However, the company revised down its estimate for a write-off related to raw materials purchased during the pandemic to make vaccines. It now expects a write-off of about \u20ac600mn, down from the up to \u20ac900mn it flagged last month, as it concluded some of the charges had already been reflected in last year\u2019s accounts.\u00a0\u00a0<\/p>\n<p>The update comes as Covid vaccine makers have scaled back their expectations for vaccine sales in recent weeks, and investors have grown wary about unpredictable demand for jabs.<\/p>\n<p>Jens Holstein, chief financial officer of BioNTech, said the company had reduced costs for 2023 in line with the lower than expected revenue.\u00a0<\/p>\n<p>\u201cIn the third quarter, we continued to invest in our capabilities and our portfolio of innovative product candidates while strengthening the financial position of BioNTech. About \u20ac17bn in cash and security investments provide strategic flexibility and is a major strength, especially in these days, where financial stability is key,\u201d he said.\u00a0<\/p>\n<p>BioNTech now expects to spend between \u20ac1.8bn and \u20ac2bn on research and development this year, compared with its previous guidance of between \u20ac2.4bn to \u20ac2.6bn. It has also cut the top end of its expectations for capital expenditure by half, and reduced forecasts for sales, general and administrative expenses by up to \u20ac100mn.\u00a0<\/p>\n<p>BioNTech\u2019s update comes after Pfizer cut its forecasts for the Covid vaccine last month, and rival Moderna said last week that it expected sales at the low end of its guidance, as fewer people line up to have booster shots this autumn. BioNTech said it anticipated fewer first doses and lower boosting compared with previous years. But it also added that the revenue cut was partly the result of later than anticipated regulatory approvals, which delayed national vaccination programmes and pushed expected sales into future periods.\u00a0<\/p>\n<p>In the third quarter, BioNTech beat expectations to report diluted earnings of 67 cents per share, higher than the consensus forecast for a loss of 35 cents per share. Net profit fell more than 90 per cent to \u20ac160.6mn from the same period the year before.\u00a0<\/p>\n<p>Sales were \u20ac895.3mn in the quarter, slightly above the average analyst estimate for \u20ac865.8mn, but far lower than the \u20ac3.5bn in the third quarter last year.\u00a0<\/p>\n<p>BioNTech is investing its Covid vaccine windfall in innovative oncology treatments, many of which are in early stage trials and will not reach the market for several years.<\/p>\n<p>U\u011fur \u015eahin, BioNTech\u2019s chief executive, said the company had recently added antibody drug conjugates, one of a newly popular drug class that aims to be more targeted than chemotherapy.\u00a0<\/p>\n<p>\u201cOur strategy focuses on assembling a diverse toolbox of complementary technologies to deliver novel therapies, aiming to improve the standard of care for cancer patients,\u201d he said. \u201cWe combine our internal innovation engine with a high-performance partnership model to transform healthcare and improve patients\u2019 quality of life.\u201d<\/p>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/www.ft.com\/content\/d5b1f377-a34d-4a7a-86b7-2c833d860110\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Unlock the Editor\u2019s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. BioNTech has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":{"0":"post-10254","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-business"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BioNTech cuts revenue forecast on lower demand for Covid jabs | inFundPros<\/title>\n<meta name=\"description\" content=\"Unlock the Editor\u2019s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.BioNTech has slashed about \u20ac1bn\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/infundpros.com\/?p=10254\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioNTech cuts revenue forecast on lower demand for Covid jabs | inFundPros\" \/>\n<meta property=\"og:description\" content=\"Unlock the Editor\u2019s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.BioNTech has slashed about \u20ac1bn\" \/>\n<meta property=\"og:url\" content=\"https:\/\/infundpros.com\/?p=10254\" \/>\n<meta property=\"og:site_name\" content=\"inFundPros\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-06T15:45:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-wall.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Press Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Press Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/infundpros.com\/?p=10254#article\",\"isPartOf\":{\"@id\":\"https:\/\/infundpros.com\/?p=10254\"},\"author\":{\"name\":\"Press Room\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff\"},\"headline\":\"BioNTech cuts revenue forecast on lower demand for Covid jabs\",\"datePublished\":\"2023-11-06T15:45:50+00:00\",\"dateModified\":\"2023-11-06T15:45:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/infundpros.com\/?p=10254\"},\"wordCount\":552,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/infundpros.com\/#organization\"},\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/infundpros.com\/?p=10254#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/infundpros.com\/?p=10254\",\"url\":\"https:\/\/infundpros.com\/?p=10254\",\"name\":\"BioNTech cuts revenue forecast on lower demand for Covid jabs | inFundPros\",\"isPartOf\":{\"@id\":\"https:\/\/infundpros.com\/#website\"},\"datePublished\":\"2023-11-06T15:45:50+00:00\",\"dateModified\":\"2023-11-06T15:45:50+00:00\",\"description\":\"Unlock the Editor\u2019s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.BioNTech has slashed about \u20ac1bn\",\"breadcrumb\":{\"@id\":\"https:\/\/infundpros.com\/?p=10254#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/infundpros.com\/?p=10254\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/infundpros.com\/?p=10254#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/infundpros.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioNTech cuts revenue forecast on lower demand for Covid jabs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/infundpros.com\/#website\",\"url\":\"https:\/\/infundpros.com\/\",\"name\":\"Fintech Advance\",\"description\":\"Latest Finance and Tech News and Updates\",\"publisher\":{\"@id\":\"https:\/\/infundpros.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/infundpros.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/infundpros.com\/#organization\",\"name\":\"Fintech Advance\",\"url\":\"https:\/\/infundpros.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"contentUrl\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"width\":409,\"height\":70,\"caption\":\"Fintech Advance\"},\"image\":{\"@id\":\"https:\/\/infundpros.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff\",\"name\":\"Press Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"contentUrl\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"caption\":\"Press Room\"},\"sameAs\":[\"https:\/\/infundpros.com\"],\"url\":\"https:\/\/infundpros.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioNTech cuts revenue forecast on lower demand for Covid jabs | inFundPros","description":"Unlock the Editor\u2019s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.BioNTech has slashed about \u20ac1bn","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/infundpros.com\/?p=10254","og_locale":"en_US","og_type":"article","og_title":"BioNTech cuts revenue forecast on lower demand for Covid jabs | inFundPros","og_description":"Unlock the Editor\u2019s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.BioNTech has slashed about \u20ac1bn","og_url":"https:\/\/infundpros.com\/?p=10254","og_site_name":"inFundPros","article_published_time":"2023-11-06T15:45:50+00:00","og_image":[{"width":1920,"height":1200,"url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-wall.jpg","type":"image\/jpeg"}],"author":"Press Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Press Room","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/infundpros.com\/?p=10254#article","isPartOf":{"@id":"https:\/\/infundpros.com\/?p=10254"},"author":{"name":"Press Room","@id":"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff"},"headline":"BioNTech cuts revenue forecast on lower demand for Covid jabs","datePublished":"2023-11-06T15:45:50+00:00","dateModified":"2023-11-06T15:45:50+00:00","mainEntityOfPage":{"@id":"https:\/\/infundpros.com\/?p=10254"},"wordCount":552,"commentCount":0,"publisher":{"@id":"https:\/\/infundpros.com\/#organization"},"articleSection":["Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/infundpros.com\/?p=10254#respond"]}]},{"@type":"WebPage","@id":"https:\/\/infundpros.com\/?p=10254","url":"https:\/\/infundpros.com\/?p=10254","name":"BioNTech cuts revenue forecast on lower demand for Covid jabs | inFundPros","isPartOf":{"@id":"https:\/\/infundpros.com\/#website"},"datePublished":"2023-11-06T15:45:50+00:00","dateModified":"2023-11-06T15:45:50+00:00","description":"Unlock the Editor\u2019s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.BioNTech has slashed about \u20ac1bn","breadcrumb":{"@id":"https:\/\/infundpros.com\/?p=10254#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/infundpros.com\/?p=10254"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/infundpros.com\/?p=10254#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/infundpros.com\/"},{"@type":"ListItem","position":2,"name":"BioNTech cuts revenue forecast on lower demand for Covid jabs"}]},{"@type":"WebSite","@id":"https:\/\/infundpros.com\/#website","url":"https:\/\/infundpros.com\/","name":"Fintech Advance","description":"Latest Finance and Tech News and Updates","publisher":{"@id":"https:\/\/infundpros.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/infundpros.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/infundpros.com\/#organization","name":"Fintech Advance","url":"https:\/\/infundpros.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/infundpros.com\/#\/schema\/logo\/image\/","url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","contentUrl":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","width":409,"height":70,"caption":"Fintech Advance"},"image":{"@id":"https:\/\/infundpros.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff","name":"Press Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/infundpros.com\/#\/schema\/person\/image\/","url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","contentUrl":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","caption":"Press Room"},"sameAs":["https:\/\/infundpros.com"],"url":"https:\/\/infundpros.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/10254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10254"}],"version-history":[{"count":0,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/10254\/revisions"}],"wp:attachment":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}